Advanced search
Publication Cover
International Journal of Radiation Biology Volume 78, 2002 - Issue 8
Submit an article Journal homepage
254
Views
76
CrossRef citations to date
0
Altmetric
Research Article

Anti-apoptotic Bcl-2 proteins: structure, function and relevance for radiation biology

C. Belka Department of Radiation Oncology, University Tübingen, Hoppe Seyler Str. 3, D-72076 Tübingen, Germany
&
W. Budach Department of Radiation Oncology, University Tübingen, Hoppe Seyler Str. 3, D-72076 Tübingen, Germany
Pages 643-658 | Published online: 03 Jul 2009

  • AALTOMAA, S., ESKELINEN, M. and LIPPONEN, P., 1999, Expression of cyclin A and D proteins in prostate cancer and their relation to clinopathological variables and patient survival. Prostate, 38, 175-182.
  • ALDRIDGE, D. R., ARENDS, M. J. and RADFORD, I. R., 1995, Increasing the susceptibility of the rat 208F fibroblast cell line to radiation-induced apoptosis does not alter its clonogenic survival dose--response. British Journal of Cancer, 71, 571-577.
  • ANNIS, M. G., ZAMZAMI, N., ZHU, W., PENN, L. Z., KROEMER, G., LEBER, B. and ANDREWS, D. W., 2001, Endoplasmic reticulum localized Bcl-2 prevents apoptosis when redistribution of cytochrome c is a late event. Oncogene, 20, 1939-1952.
  • ASCHOFF, A. P., OTT, U., FUNFSTUCK, R., STEIN, G. and JIRIKOWSKI, G. F., 1999, Colocalization of BAX and BCL-2 in small intestine and kidney biopsies with different degrees of DNA fragmentation. Cell Tissue Research, 296, 351-357.
  • ATHANASSIADOU, P., PETRAKAKOU, E., LIOSSI, A., NAKOPOULOU, L., ZERVA, C., DIMOPOULOS, A. and ATHANASSIADES, P., 1999, Prognostic significance of p53, bcl-2 and EGFR in carcinoma of the endometrium. Ada Cytologica, 43, 1039-1044.
  • BAFFY, G., MIYASHITA, T., WILLIAMSON, J. R. and REED, J. C., 1993, Apoptosis induced by withdrawal of interleukin-3 (IL-3) from an IL-3-dependent hematopoietic cell line is associated with repartitioning of intracellular calcium and is blocked by enforced Bcl-2 oncoprotein production. Journal of Biological Chemistry, 268, 6511-6519.
  • BELKA, C., KMPPERS, P., RUDNER, J., FALTIN, H., BAMBERG, M. and BUDACH, W., 2000a, MEK1 and ERK1/2 kinases as targets for the modulation of radiation responses. Anticancer Research, 20, 3243-3249.
  • BELKA, C., MARINI, P., LEPPLE-WIENHUES, A., BUDACH, W., JEKLE, A., Los, M., LANG, F., SCHULZE-OSTHOFF, K., GULBINS, E. and BAMBERG, M., 1999, The tyrosine kinase lck is required for CD95-independent caspase-8 activation and apoptosis in response to ionizing radiation. Oncogene, 18, 4983-4992.
  • BELKA, C., RUDNER, J., WESSELBORG, S., STEPCZYNSKA, A., MARINI, P., LEPPLE-WIENHUES, A, FALTIN, H., BAMBERG, M., BUDACH, W. and SCHULZE-OSTHOFF, K., 2000b, Differential role of caspase-8 and BID activation during radiation- and CD95-induced apoptosis. Oncogene, 19, 1181-1190.
  • BELKA, C., SCHMID, B., MARINI, P., DURAND, E., RUDNER, J., FALTIN, H., BAMBERG, M., SCHULZE-OSTHOFF, K. and BUDACH, W., 2001, Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL. Oncogene, 20, 2190-2196.
  • BOISE, L. H., GONZALEZ-GARCIA, M., POSTEMA, C. E., DING, L., LINDSTEN, T., TURKA, L. A, MAO, X., NUNEZ, G. and THOMPSON, C. B., 1993, bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell, 74, 597-608.
  • BOSARI, S., MONEGHINI, L., GRAZIANI, D., LEE, A K., MURRAY, J. J., COGGI, G. and VIALE, G., 1995, bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Human Pathology, 26, 534-540.
  • BOSSY-WETZEL, E., NEWMEYER, D. D. and GREEN, D. R., 1998, Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. EMBO Journal, 17, 37-49.
  • BOUILLET, P., METCALF, D., HUANG, D. C., TARLINTON, D. M., KAY, T. W., KONTGEN, F., ADAMS, J. M. and STRASSER, A, 1999, Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science, 286, 1735-1738.
  • BRADY, H. J., GIL-GOMEZ, G., KIRBERG, J. and BERNS, A. J., 1996, Bax alpha perturbs T cell development and affects cell cycle entry of T cells. EMBO Journal, 15, 6991-7001.
  • BRUSTUGUN, O. T., FLADMARK, K. E., DOSKELAND, S. O., ORRENIUS, S. and ZHIVOTOVSKY, B., 1998, Apoptosis induced by microinjection of cytochrome c is caspase-dependent and is inhibited by Bcl-2. Cell Death and Differentiation, 5, 660-668.
  • BYLUND, A., STATTIN, P., WIDMARK, A and BERGH, A, 1998, Predictive value of bcl-2 immunoreactivity in prostate cancer patients treated with radiotherapy. Radiotherapy and Oncology, 49, 143-148.
  • CHANG, B. S., MINN, A. J., MUCHMORE, S. W., FESIK, S. W. and THOMPSON, C. B., 1997, Identification of a novel regulatory domain in BcI-X(L) and Bcl-2. EMBO Journal, 16, 968-977.
  • CHAU, B. N., CHENG, E. H., KERR, D. A and HARDWICK, J. M., 2000, Aven, a novel inhibitor of caspase activation, binds Bcl-xL and Apaf-1. Molecular Cell, 6, 31-40.
  • CHENG, E. H., LEVINE, B., BOISE, L. H., THOMPSON, C. B. and HARDWICK, J. M., 1996, Bax-independent inhibition of apoptosis by Bel-XL. Nature, 379, 554-556.
  • CHENG, E. H., WEI, M. C., WEILER, S., FLAVELL, R. A., MAK, T. W., LINDSTEN, T. and KORSMEYER, S. J., 2001, BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX-and BAK-mediated mitochondrial apoptosis. Molecular Cell, 8, 705-711.
  • CHINNAIYAN, A. M., O'ROURKE, K., LANE, B. R. and DIXIT, V. M., 1997, Interaction of CED-4 with CED-3 and CED-9: a molecular framework for cell death. Science, 275, 1122-1126.
  • CHITTENDEN, T., HARRINGTON, E. A, O'CONNOR, R., FLEMINGTON, C., LUTZ, R. J., EVAN, G. I. and GUILD, B. C., 1995, Induction of apoptosis by the Bcl-2 homologue Bak. Nature, 374, 733-736.
  • CHRYSOMALI, E., GREENSPAN, J. S., DEKKER, N., GREENSPAN, D. and REGEZI, J. A., 1996, Apoptosis-associated proteins in oral hairy leukoplakia. Oral Diseases, 2, 279-284.
  • CLARKE, M. R., SAFATLE-RIBEIRO, A V., RIBEIRO, U., SAKAI, P. and REYNOLDS, J. C., 1997, bcl-2 protein expression in gastric remnant mucosa and gastric cancer 15 or more years after partial gastrectomy. Modem Pathology, 10, 1021-1027.
  • CONRADT, B. and HORVITZ, H. R., 1998, The C. elegans protein EGL-1 is required for programmed cell death and interacts with the Bcl-2-like protein CED-9. Cell, 93, 519-529.
  • COOKE, P. W., JAMES, N. D., GANESAN, R., BURTON, A., YOUNG, L. S. and WALLACE, D. M., 2000, Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy. BJU International, 85, 829-835.
  • COSTA, A., LICITRA, L., VENERONI, S., DAIDONE, M. G., GRANDI, C., CAVINA, R., MOLINARI, R. and SILVESTRINI, R., 1998, Biological markers as indicators of pathological response to primary chemotherapy in oral-cavity cancers. International Journal of Cancer, 79, 619-623.
  • COX, G., WALKER, R. A., MULLER, S., ABRAMS, K. R., STEWARD, W. P. and O'BYRNE, K. J., 2000, Does immunointensity account for the differences in prognostic significance of Bcl-2 expression in non-small cell lung cancer? Pathology Oncology Research, 6, 87-92.
  • DANIEL, P. T., PUN, K. T., RITSCHEL, S., STURM, I., HOLLER, J., DORKEN, B. and BROWN, R., 1999, Expression of the death gene Bik/Nbk promotes sensitivity to drug-induced apoptosis in corticosteroid-resistant T-cell lymphoma and prevents tumour growth in severe combined immunodeficient mice. Blood, 94, 1100-1107.
  • DEWEY, W. C., LING, C. C. and MEYN, R. E., 1995, Radiation-induced apoptosis: relevance to radiotherapy. International Journal of Radiation Oncology, Biology, Physics, 33, 781-796.
  • DIMMELER, S., BREITSCHOPF, K., HAENDELER, J. and ZEIHER, A. M., 1999, Dephosphorylation targets Bcl-2 for ubiquitin-dependent degradation: a link between the apoptosome and the proteasome pathway. Journal of Experimental Medicine, 189, 1815-1822.
  • ELKHUIZEN, P. H., VAN SLOOTEN, H. J., CLAHSEN, P. C., HERMANS, J., VANDE VELDE, C. J., VAN DEN BROEK, L. C. and VANDE VIJVER, M. J., 2000, High local recurrence risk after breast-conserving therapy in node-negative premenopausal breast cancer patients is greatly reduced by one course of perioperative chemotherapy: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study. Journal of Clinical Oncology, 18, 1075-1083.
  • ENGELS, I. H., STEPCZYNSKA, A., STROH, C., LAUBER, K., BERG, C., SCHWENZER, R., WAJANT, H., JANICKE, R. U., PORTER, A. G., BELKA, C., GREGOR, M., SCHULZE-OSTHOFF, K. and WESSELBORG, S., 2000, Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis. Oncogene, 19, 4563-4573.
  • FOYOUZI-YOUSSEFI, R., ARNAUEKAU, S., BORNER, C., KELLEY, W. L., TSCHOPP, J., LEW, D. P., DEMAUREX, N. and KRAUSE, K. H., 2000, Bcl-2 decreases the free Ca2 + concentration within the endoplasmic reticulum. Proceedings of the National Academy of Sciences, USA, 97, 5723-5728.
  • FRIEDMAN, M., GREY, P., VENKATESAN, T. K., BLOCH, I., CHAWLA, P., CALDARELLI, D. D. and COON, J. S., 1997, Prognostic significance of Bcl-2 expression in localized squamous cell carcinoma of the head and neck. Annals of Otology, Rhinology, and Laryngology, 106, 445-450.
  • FURUKAWA, Y., IWASE, S., KIKUCHI, J., TERUI, Y., NAKAMURA, M., YAMADA, H., KAND, Y. and MATSUDA, M., 2000, Phosphorylation of Bcl-2 protein by CDC2 kinase during G2/M phases and its role in cell cycle regulation. Journal of Biological Chemistry, 275, 21661-21667.
  • GALLO, O., BODDI, V., CALZOLARI, A., SIMONETTI, L., TROVATI, M. and BlANCHI, S., 1996, bcl-2 protein expression correlates with recurrence and survival in early stage head and neck cancer treated by radiotherapy. Clinical Cancer Research, 2, 261-267.
  • GARTNER, A., MILSTEIN, S., AHMED, S., HODGKIN, J. and HENGARTNER, M. O., 2000, A conserved checkpoint pathway mediates DNA damage-induced apoptosis and cell cycle arrest in C. elegans. Molecular Cell, 5, 435-443.
  • GASPARINI, G., BEVILACQUA, P., BONDLDI, E., TESTOLIN, A., GALASSI, A., VERDERIO, P., BORACCHI, P., GUGLIELMI, R. B. and PEZZELLA, F., 1995, Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy. Clinical Cancer Research, 1, 1375-1383.
  • GIATROMANDLAKI, A., KOUKOURAKIS, M., ZARAMBO UKAS, T., SKORDALAKI, A., ARAPANTONI, P., GEORGOULIAS, V. and FOUNTZILAS, G., 1998, p53 and bcl-2 expression in locally advanced squamous cell head--neck cancer treated with platinum based chemotherapy and radiotherapy. Anticancer Research, 18, 4685-4692.
  • GOLDBLUM, J. R. and RlCE, T. W., 1995, bcl-2 protein expression in the Barrett's metaplasia--dysplasia--carcinoma sequence. Modem Pathology, 8, 866-869.
  • HAAS, S., BOSCH, F. X., KLEIN-KUHNE, W., NOLLERT, J., RUDAT, V., CONRADT, C. and DIETZ, A., 1999, Prognostic significance of cell-cycle regulatory proteins for outcome after primary radiochemotherapy in patients with advanced head and neck cancer. HMO, 47, 777-786.
  • HACKI, J., EGGER, L., MONNEY, L., CONUS, S., ROSSE, T., FELLAY, I. and BORNER, C., 2000, Apoptotic crosstalk between the endoplasmic reticulum and mitochondria controlled by Bcl-2. Oncogene, 19, 2286-2295.
  • HARIMA, Y., HARIMA, K., SHIKATA, N., OKA, A., OHNISHI, T. and TANAKA, Y., 1998, Bax and Bcl-2 expressions predict response to radiotherapy in human cervical cancel. Journal of Cancer Research and Clinical Oncology, 124, 503-510.
  • HARIMA, Y., NAGATA, K., HARIMA, K., OKA, A., OSTAPENKO, V. V., SHIKATA, N., OHNISHI, T. and TANAKA, Y., 2000, Bax and Bcl-2 protein expression following radiation therapy versus radiation plus thermoradiotherapy in stage IIIB cervical carcinoma. Cancer, 88, 132-138.
  • HAUSMANN, G., O'REILLY, L. A., VAN DRIEL, R., BEAUMONT, J. G., STRASSER, A., ADAMS, J. M. and HUANG, D. C., 2000, Proapoptotic apoptosis protease-activating factor 1 (Apaf-1) has a cytoplasmic localization distinct from Bcl-2 or Bcl-x(L). Journal of Cell Biology, 149, 623-34.
  • HE, H., LAM, M., MCCORMICK, T. S. and DISTELHORST, C. W., 1997, Maintenance of calcium homeostasis in the endoplasmic reticulum by Bcl-2. Journal of Cell Biology, 138, 1219-1228.
  • HENDERSON, S., ROWE, M., GREGORY, C., GROOM-CARTER, D., WANG, F., LONGNECKER, R., KIEFF, E. and RICKINSON, A., 1991, Induction of bcl-2 expression by Epstein--Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell, 65, 1107-1115.
  • HSU, S. Y., KAIPIA, A., MCGEE, E., LOMELI, M. and HSUEH, A. J., 1997, Bok is a pro-apoptotic Bcl-2 protein with restricted expression in reproductive tissues and heterodimerizes with selective anti-apoptotic Bcl-2 family members. Proceedings of the National Academy of Sciences, USA, 94, 12401-12406.
  • HSU, S. Y., LIN, P. and HSUEH, A. J., 1998, BOD (Bcl-2-related ovarian death gene) is an ovarian BH 3 domain-containing proapoptotic Bcl-2 protein capable of dimerization with diverse antiapoptotic Bcl-2 members. Molecular Endocrinology, 12, 1432-1440.
  • HUANG, D. C., HAHNE, M., SCHROETER, M., FREI, K., FONTANA, A., VILLUNGER, A., NEWTON, K., TSCHOPP, J. and STRASSER, A., 1999, Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-x(L). Proceedings of the National Academy of Sciences, USA, 96, 14871-14876.
  • HUANG, D. C., O'REILLY, L. A., STRASSER, A. and CORY, S., 1997, The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO Journal, 16, 4628-4638.
  • HUANG, D. C., TSCHOPP, J. and STRASSER, A., 2000, Bcl-2 does not inhibit cell death induced by the physiological Fas ligand: implications for the existence of type I and type II cells. Cell Death and Differentiation, 7, 754-755.
  • HWANG, J. H., LIM, S. C., KIM, Y. C., PARK, K. O., AHN, S. J. and CHUNG, W. K., 2001, Apoptosis and bcl-2 expression as predictors of survival in radiation-treated non-smallcell lung cancer. International Journal of Radiation Oncology, Biology, Physics, 50, 13-18.
  • JAGER, J. J., JANSEN, R. L., ARENDS, J. W., JOOSTEN-ACHJANIE, S., VOLOVICS, L., SCHOUTEN, L. J., DE JONG, J. M., MEYENFELDT, M. F. and BLIJHAM, G. H., 2000, Antiapoptotic phenotype is associated with decreased locoregional recurrence rate in breast cancer. Anticancer Research, 20, 1269-1275.
  • JOENSUU, H., PYLKKANEN, L. and TOIKKANEN, S., 1994, Bcl-2 protein expression and long-term survival in breast cancer. American Journal of Pathology, 145, 1191-1198.
  • JUO, P., KUO, C. J., YUAN, J. and BLENIS, J., 1998, Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. Current Biology, 8, 1001-1008.
  • JURGENSMEIER, J. M., XIE, Z., DEVERAUX, Q., ELLERBY, L., BREDESEN, D. and REED, J. C., 1998, Bax directly induces release of cytochrome c from isolated mitochondria. Proceedings of the National Academy of Sciences, USA, 95, 4997-5002.
  • KAMADA, S., SHIMONO, A., SHINTO, Y., TSUJIMURA, T., TAKAHASHI, T., NODA, T., KITAMURA, Y., KONDOH, H. and TSUJIMOTO, Y., 1995, bcl-2 deficiency in mice leads to pleiotropic abnormalities: accelerated lymphoid cell death in thymus and spleen, polycystic kidney, hair hypopigmentation, and distorted small intestine. Cancer Research, 55, 354-359.
  • KATAOKA, T., HOLLER, N., MICHEAU, O., MARTINON, F., TINEL, A., HOFMANN, K. and TSCHOPP, J., 2001, Bcl-rambo, a novel Bcl-2 homologue that induces apoptosis via its unique c-terminal extension. Journal of Biological Chemistry, 276, 19548-19554.
  • KELEKAR, A., CHANG, B. S., HARLAN, J. E., FESIK, S. W. and THOMPSON, C. B., 1997, Bad is a BH3 domain-containing protein that forms an inactivating dimer with Bcl-XL. Molecular and Cellular Biology, 17, 7040-7046.
  • KENNY, F. S., PINDER, S. E., ELLIS, I.O., GEE, J. M., NICHOLSON, R. I., BRYCE, R. P. and ROBERTSON, J. F., 2000, Gamma linolenic acid with tamoxifen as primary therapy in breast cancer. International Journal of Cancer, 85, 643-648.
  • KIKUCHI, Y., DINJENS, W. N. and BOSMAN, F. T., 1997, Proliferation and apoptosis in proliferative lesions of the colon and rectum. Virchows Archiv, 431, 111-117.
  • KONTUREK, P. C., BRZOZDWSKI, T., KONTUREK, S. J., PAJDO, R., KONTUREK, J. E., KWIECIEN, S., TAUT, A. and HAHN, E. G., 1999, Apoptosis in gastric mucosa with stress-induced gastric ulcers. Journal of Physiology and Pharmacology, 50, 211-225.
  • KOPP, R., KRAMLING, H. J., CRAMER, C., DIEBOLD, J., BARETTON, G. and SCHILDBERG, F. W., 1998, Prognostic significance of apoptosis inducers/inhibitors in stomach carcinoma with/without adjuvant intraoperative radiotherapy (IORT). Langenbecks Archiv Chirurgie Suppl, 115, 1360-1362.
  • KOZOPAS, K. M., YANG, T., BUCHAN, H. L., ZHOU, P. and CRAIG, R. W., 1993, MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proceedings of the National Academy of Sciences, USA, 90, 3516-3520.
  • KYPRIANOU, N., KING, E. D., BRADBURY, D. and RHEE, J. G., 1997, bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. International Journal of Cancer, 70, 341-348.
  • LANGENDIJK, H., THUNNISSEN, E., ARENDS, J. W., DE JONG, J., TEN VELDE, G., LAMERS, R., GUINEE, D., HOLDEN, J. and WOUTERS, M., 2000, Cell proliferation and apoptosis in stage III inoperable non-small cell lung carcinoma treated by radiotherapy. Radiotherapy and Oncology, 56, 197-207.
  • LEE, S. T., HOEFLICH, K. P., WASFY, G. W., WOODGETT, J. R., LEBER, B., ANDREWS, D. W., HEDLEY, D. W. and PENN, L. Z., 1999, Bcl-2 targeted to the endoplasmic reticulum can inhibit apoptosis induced by Myc but not etoposide in Rat-1 fibroblasts. Oncogene, 18, 3520-3528.
  • LI, P., NIJHAWAN, D., BUDIHARDJO, I., SRINIVASULA, S. M., AHMAD, M., ALNEMRI, E. S. and WANG, X., 1997, Cytochrome c and dATP-dependent formation of Apaf-1 /caspase-9 complex initiates an apoptotic protease cascade. Cell, 91, 479-489.
  • LIN, E. Y., ORLOFSKY, A., BERGER, M. S. and PRYSTOWSKY, M. B., 1993, Characterization of Al, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2. Journal of Immunology, 151, 1979-1988.
  • LINETTE, G. P., LI, Y., ROTH, K. and KORSMEYER, S. J., 1996, Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation. Proceedings of the National Academy of Sciences, USA, 93, 9545-9552.
  • LOWE, S. W., SCHMITT, E. M., SMITH, S. W., OSBORNE, B. A. and JACKS, T., 1993, p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature, 362, 847-849.
  • LUO, X., BUDIHARDIO, I., ZOU, H., SLAUGHTER, C. and WANG, X., 1998, Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell, 94, 481-490.
  • MARZO, I., BRENNER, C., ZAMZAMI, N., JURGENSMEIER, J. M., SUSIN, S. A., VIEIRA, H. L., PREVOST, M. C., XIE, Z., MATSUYAMA, S., REED, J. C. and KROEMER, G., 1998, Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science, 281, 2027-2031.
  • MASUDA, M., SHINOKUMA, A., HIRAKAWA, N., NAKASHIMA, T. and KOMIYAMA, S., 1998, Expression of bcl-2-, p53, and Ki-67 and outcome of patients with primary nasopharyngeal carcinomas following DNA-damaging treatment. Head and Neck, 20, 640-644.
  • MATOLCSY, A., CASALI, P., WARNKE, R. A. and KNOWLES, D. M., 1996, Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene. Blood, 88, 3937-3944.
  • MAZEL, S., BURTRUM, D. and PETRIE, H. T., 1996, Regulation of cell division cycle progression by bcl-2 expression: a potential mechanism for inhibition of programmed cell death. Journal of Experimental Medicine, 183, 2219-2226.
  • MERRY, D. E., VEIS, D. J., HICKEY, W. F. and KORSMEYER, S. J., 1994, bcl-2 protein expression is widespread in the developing nervous system and retained in the adult PNS. Development, 120, 301-311.
  • MICHAELIDIS, T. M., SENDTNER, M., COOPER, J. D., AIRAKSINEN, M. S., HOLTMANN, B., MEYER, M. and THOENEN, H., 1996, Inactivation of bcl-2 results in progressive degeneration of motoneurons, sympathetic and sensory neurons during early postnatal development. Neuron, 17, 75-89.
  • MINN, A. J., KETTLUN, C. S., LIANG, H., KELEKAR, A., VANDER HEIDEN, M. G., CHANG, B. S., FESIK, S. W., FILL, M. and THOMPSON, C. B., 1999, Bd-xL regulates apoptosis by heterodimerization-dependent and -independent mechanisms. EMBO Journal, 18, 632-643.
  • MIRKOVIC, N., VOEHRINGER, D. W., STORY, M. D., MCCONKEY, D. J., MCDONNELL, T. J. and MEYN, R. E., 1997, Resistance to radiation-induced apoptosis in BcI-2-expressing cells is reversed by depleting cellular thiols. Oncogene, 15, 1461-1470.
  • MIURA, M., ZHU, H., ROTELLO, R., HARTWIEG, E. A. and YUAN, J., 1993, Induction of apoptosis in fibroblasts by IL-1 beta-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3. Cell, 75, 653-660.
  • MIYASHITA, T. and REED, J. C., 1995, Tumour suppressor p53 is a direct transcriptional activator of the human bax gene. Cell, 80, 293-299.
  • MORALES-DUCRET, C. R., VANDE RUN, M. and SMOLLER, B. R., 1995, bcl-2 expression in melanocytic nevi. Insights into the biology of dermal maturation. Archives of Dermatology, 131, 915-918.
  • MORIISHI, K., HUANG, D. C., CORY, S. and ADAMS, J. M., 1999, Bcl-2 family members do not inhibit apoptosis by binding the caspase activator Apaf-1. Proceedings of the National Academy of Sciences, USA, 96, 9683-9688.
  • MUCHMORE, S. W., SATTLER, M., LIANG, H., MEADOWS, R. P., HARLAN, J. E., YOON, H. S., NETTESHEIM, D., CHANG, B. S., THOMPSON, C. B., WONG, S. L., NG, S. L. and FESIK, S. W., 1996, X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature, 381, 335-341.
  • MUZIO, M., CHINNAIYAN, A. M., KISCHKEL, F. C., O'ROURKE, K., SHEVCHENKO, A., NI, J., SCAFFIDI, C., BRETZ, J. D., ZHANG, M., GENTZ, R., MANN, M., KRAMMER, P. H., PETER, M. E. and DIXIT, V. M., 1996, FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell, 85, 817-827.
  • NAKAND, K. and VOUSDEN, K. H., 2001, PUMA, a novel proapoptotic gene, is induced by p53. Molecular Cell, 7, 683-694.
  • NAKASU, S., NAKASU, Y., NIOKA, H., NAKAJIMA, M. and HANDA, J., 1994, bcl-2 protein expression in tumours of the central nervous system. Ada Neuropathologica (Berlin), 88, 520-526.
  • NAKAYAMA, K., NEGISHI, I., KUIDA, K., SAWA, H. and LOH, D. Y., 1994, Targeted disruption of Bcl-2 alpha beta in mice: occurrence of gray hair, polycystic kidney disease, and lymphocytopenia. Proceedings of the National Academy of Sciences, USA, 91, 3700-3704.
  • NARITA, M., SHIMIZU, S., ITO, T., CHITTENDEN, T., LUTZ, R. J., MATSUDA, H. and TSUJIMOTO, Y., 1998, Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. Proceedings of the National Academy of Sciences, USA, 95, 14681-14686.
  • NEWCOMB, E. W., COHEN, H., LEE, S. R., BHALLA, S. K., BLOOM, J., HAYES, R. L. and MILLER, D. C., 1998, Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathology, 8, 655-667.
  • O'CONNOR, L., STRASSER, A., O'REILLY, L. A., HAUSMANN, G., ADAMS, J. M., CORY, S. and HUANG, D. C., 1998, Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO Journal, 17, 384-395.
  • ODA, E., OHKI, R., MURASAWA, H., NEMOTO, J., SHIBUE, T., YAMASHITA, T., TOKINO, T., TANIGUCHI, T. and TANAKA, N., 2000, Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science, 288, 1053-1058.
  • OHMORI, T., ASAHI, S., SATO, C., MAKI, F., MASUMOTO, A. and OKADA, K., 1999, Bcl-2 protein expression and gut neurohormonal polypeptide/amine production in colorectal carcinomas and tumour-neighboring mucosa, which closely correlate to the occurrence of tumour. Histology and Histopathology, 14, 37-44.
  • OHSAKI, Y., TOYOSHIMA, E., FUJIUCHI, S., MATSUI, H., HIRATA, S., MIYOKAWA, N., KUBO, Y. and KIKUCHI, K., 1996, bcl-2 and p53 protein expression in non-small cell lung cancers: correlation with survival time. Clinical Cancer Research, 2, 915-920.
  • OJALA, P. M., YAMAMOTO, K., CASTANOS-VELEZ, E., BIBERFELD, P., KORSMEYER, S. J. and MAKELA, T. P., 2000, The apoptotic v-cyclin-CDK6 complex phosphorylates and inactivates Bcl-2. Nature Cell Biology, 2, 819-825.
  • OLOPADE, O. I., ADEYANJU, M. O., SAFA, A. R., HAGOS, F., MICK, R., THOMPSON, C. B. and RECANT, W. M., 1997, Overexpression of BCL-x protein in primary breast cancer is associated with high tumour grade and nodal metastases. Cancer Journal of Scientific American, 3, 230-237.
  • OLTVAI, Z. N., MILLIMAN, C. L. and KORSMEYER, S. J., 1993, Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 74, 609-619.
  • ONG, F., MOONEN, L. M., GALLEE, M. P., TENBOSCH, C., ZERP, S. F., HART, A. A., BARTELINK, H. and VERHEIJ, M., 2001, Prognostic factors in transitional cell cancer of the bladder an emerging role for Bcl-2 and p53. Radiotherapy and Oncology, 61, 169-175.
  • O'REILLY, L. A., HARRIS, A. W. and STOASSER, A., 1997, bcl-2 transgene expression promotes survival and reduces proliferation of CD3-CD4-CD8-T cell progenitors. International Immunology, 9, 1291-1301.
  • PAUTIEL, O., ZELENETZ, A., SVERDLIN, I., GORDON, L. and BEN-YEHUDA, D., 2000, Translocation t(14;18) in healthy individuals: preliminary study of its association with family history and agricultural exposure. Annals of Oncology, 11, 75-80.
  • PILLAI, M. R., JAYAPRAKASH, P. G. and NAIR, M. K., 1999, bcl-2 immunoreactivity but not p53 accumulation associated with tumour response to radiotherapy in cervical carcinoma. Journal of Cancer Research and Clinical Oncology, 125, 55-60.
  • PINION, P., FERRARI, D., MAGALHAES, P., SCHULZE-OSTHOFF, K., DI VIRGILIO, F., POZZAN, T. and RIZZUTO, R., 2000, Reduced loading of intracellular Ca(2+) stores and downregulation of capacitative Ca(2 +) influx in Bcl-2-overexpressing cells. Journal of Cell Biology, 148, 857-862.
  • PINTON, P., FERRARI, D., RAPIZZI, E., DI VIRGILIO, F. D., POZZAN, T. and RIZZUTO, R., 2001, The Ca2+ concentration of the endoplasmic reticulum is a key determinant of ceramide-induced apoptosis: significance for the molecular mechanism of Bcl-2 action. EMBO Journal, 20, 2690-2701.
  • POLLACK, A., WU, C. S., CZERNIAK, B., ZAGARS, G. K., BENEDICT, W. F. and MCDONNELL, T. J., 1997, Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clinical Cancer Research, 3, 1823-1829.
  • POTTEN, C. S., 1998, Stem cells in gastrointestinal epithelium: numbers, characteristics and death. Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences, 353, 821-830.
  • PUGLISI, F., DI LORETO, C., PANIZZO, R., AVELLINI, C., FONGIONE, S., CACITTI, V. and BELTRAMI, C. A., 1996, Expression of p53 and bcl-2 and response to preoperative chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the oesophagus. Journal of Clinical Pathology, 49, 456-459.
  • RAJKUMAR, T., RAJAN, S., BARUAH, R. K., MAJHI, U., SELVALUXMI, G. and VASANTHAN, A., 1998, Prognostic significance of Bcl-2 and p53 protein expression in stage IIB and IIIB squamous cell carcinoma of the cervix. European Journal of Gynaecolgical Oncology, 19, 556-560.
  • RAKOZY, C., GRIGNON, D. J., SARKAR, F. H., SAKR, W. A., LITTOUP, P. and FORMAN, J., 1998, Expression of bcl-2, p53, and p21 in benign and malignant prostatic tissue before and after radiation therapy. Modem Pathology, 11, 892-899.
  • REHEMTULLA, A., HAMILTON, A. C., TANEJA, N., FRIDMAN, J., JUAN, T. S., MAYBA UM, J. and CHINNAIYAN, A., 1999, A caspase-resistant form of BcI-X(L), but not wild type BcI-X(L), promotes clonogenic survival after ionizing radiation. Neoplasia, 1, 63-70.
  • RIEGER, L., WELLER, M., BORNEMANN, A., SCHABET, M., DICHGANS, J. and MEYERMANN, R., 1998, BCL-2 family protein expression in human malignant glioma: a clinical-pathological correlative study. Journal of the Neurological Sciences, 155, 68-75.
  • RODEL, C., GRABENBAUER, G. G., RODEL, F., BIRKENHAKE, S., KUHN, R., MARTUS, P., ZURCHER, T., FURSICH, D., PAPADOPOULOS, T., DUNST, J., SCHROTT, K. M. and SAUER, R., 2000, Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. International Journal of Radiation Oncology, Biology, Physics, 46, 1213-1221.
  • RUDNER, J., BELKA, C., MARINI, P., WAGNER, R. J., FALTIN, H., LEPPLE-WIENHUES, A., BAMBERG, M. and BUDACH, W., 2001a, Radiation sensitivity and apoptosis in human lymphoma cells. International Journal of Radiation Biology, 77, 1-11.
  • RUDNER, J., LEPPLE-WIENHUES, A., BUDACH, W., BERSCHAUER, J., FRIEDRICH, J., SCHULZE-OSTHOFF, K. and BELKA, C., 2001b, Wild-type, mitochondrial and ER-restricted Bcl-2 inhibit DNA damage-induced apoptosis but neither affects death receptor-induced apoptosis. Journal of Cell Science, 114, 4161-4172.
  • SATTLER, M., LIANG, H., NETTESHEIM, D., MEADOWS, R. P., HARLAN, J. E., EBERSTADT, M., YOON, H. S., SHUKER, S. B., CHANG, B. S., MINN, A. J., THOMPSON, C. B. and FESIK, S. W., 1997, Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science, 275, 983-986.
  • SCAFFIDI, C., FULDA, S., SRINIVASAN, A., FRIESEN, C., LI, F., TOMASELLI, K. J., DEBATIN, K. M., KRAMMER, P. H. and PETER, M. E., 1998, Two CD95 (APO-1/Fas) signaling pathways. EMBO Journal, 17, 1675-1687.
  • SCHEID, M. P. and DURONIO, V., 1998, Dissociation of cytokine-induced phosphorylation of Bad and activation of PKB/akt: involvement of MEK upstream of Bad phosphorylation. Proceedings of the National Academy of Sciences, USA, 95, 7439-7444.
  • SCHENDEL, S. L., XIE, Z., MONTAL, M. O., MATSUYAMA, S., MONTAL, M. and REED, J. C., 1997, Channel formation by antiapoptotic protein Bcl-2. Proceedings of the National Academy of Sciences, USA, 94, 5113-5118.
  • SCHMITT, C. A., ROSENTHAL, C. T. and LOWE, S. W., 2000, Genetic analysis of chemoresistance in primary murine lymphomas. Nature Medicine, 6, 1029-1035.
  • SCOTT, N., HALE, A., DEAKIN, M., HAND, P., ADAB, F. A., HALL, C., WILLIAMS, G. T. and ELDER, J. B., 1998, A histopathological assessment of the response of rectal adenocarcinoma to combination chemo-radiotherapy: relationship to apoptotic activity, p53 and bcl-2 expression. European Journal of Surgical Oncology, 24, 169-173.
  • SEDLAK, T. W., OLTVAI, Z. N., YANG, E., WANG, K., BOISE, L. H., THOMPSON, C. B. and KORSMEYER, S. J., 1995, Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proceedings of the National Academy of Sciences, USA, 92, 7834-7838.
  • SENTMAN, C. L., SHUTTER, J. R., HOCKENBERY, D., KANAGAWA, O. and KORSMEYER, S. J., 1991, bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell, 67, 879-888.
  • SHIMIZU, S., KONISHI, A., KODAMA, T. and TSUJIMOTO, Y., 2000, BH4 domain of antiapoptotic Bcl-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death. Proceedings of the National Academy of Sciences, USA, 97, 3100-3105.
  • SHIMIZU, S., NARITA, M. and TSUJIMOTO, Y., 1999, Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature, 399, 483-487.
  • SILVESTRINI, R., BENINI, E., VENERONI, S., DAIDONE, M. G., TOMASIC, G., SQUICCIARINI, P. and SALVADORI, B., 1996, p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. Journal of Clinical Oncology, 14, 1604-1610.
  • SILVESTRINI, R., VENERONI, S., BENINI, E., DAIDONE, M. G., LUISI, A., LEUTNER, M., MAUCIONE, A., KENDA, R., ZUCALI, R. and VERONESI, U., 1997, Expression of p53, glutathione S-transferase-pi, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. Journal of the National Cancer Institute, 89, 639-645.
  • SINICROPE, F. A., EVANS, D. B., LEACH, S. D., CLEARY, K. R., FENOGLIO, C. J., LEE, J. J. and ABBRUZZESE, J. L., 1996, bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clinical Cancer Research, 2, 2015-2022.
  • SINICROPE, F. A., RUAN, S. B., CLEARY, K. R., STEPHENS, L. C., LEE, J. J. and LEVIN, B., 1995, bcl-2 and p53 oncoprotein expression during colorectal tumourigenesis. Cancer Research, 55, 237-241.
  • SPECTOR, M. S., DESNOYERS, S., HOEPPNER, D. J. and HENGARTNER, M. O., 1997, Interaction between the C. elegans cell-death regulators CED-9 and CED-4. Nature, 385, 653-656.
  • STATTIN, P., 1997, Prognostic factors in prostate cancer. Scandinavian Journal of Urology and Nephrology Supplement, 185, 1-46.
  • STENNICKE, H. R., JURGENSMEIER, J. M., SHIN, H., DEVERAUX, Q., WOLF, B. B., YANG, X., ZHOU, Q., ELLERBY, H. M., ELLERBY, L. M., BREDESEN, D., GREEN, D. R., REED, J. C., FROELICH, C. J. and SALVESEN, G. S., 1998, Procaspase-3 is a major physiologic target of caspase-8. Journal of Biological Chemistry, 273, 27084-27090.
  • STORY, M. D., VOEHRINGER, D. W., MALONE, C. G., HOBBS, M. L. and MEYN, R. E., 1994, Radiation-induced apoptosis in sensitive and resistant cells isolated from a mouse lymphoma. International Journal of Radiation Biology, 66, 659-668.
  • STRASSER, A., HARRIS, A. W., JACKS, T. and CORY, S., 1994, DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell, 79, 329-339.
  • STREFFER, J. R., RIMNER, A., RIEGER, J., NAUMANN, U., RODEMANN, H. P. and WELLER, M., 2002, Bcl-2 family proteins modulate radiosensitivity in human malignant glioma cells. Journal of Neurooncology, 56, 43-49.
  • SUSIN, S. A., LORENZO, H. K., ZAMZAMI, N., MARZO, I., SNOW, B. E., BROTHERS, G. M., MANGION, J., JACOTOT, E., COSTANTINI, P., LOEFFLER, M., LAROCHETTE, N., GOODLETT, D. R., AEBERSOLD, R., SIDEROVSKI, D. P., PENNINGER, J. M. and KROEMER, G., 1999, Molecular characterization of mitochondrial apoptosis-inducing factor. Nature, 397, 441-446.
  • TANAKA, S., LOUIE, D. C., KANT, J. A. and REED, J. C., 1992, Frequent incidence of somatic mutations in translocated BCL2 oncogenes of non-Hodgkin's lymphomas. Blood, 79, 229-237.
  • TANNAPFEL, A., NUSSLEIN, S., FIETKAU, R., KATAUNIC, A., KOCKERLING, F. and WITTEKIND, C., 1998, Apoptosis, proliferation, bax, bcl-2 and p53 status prior to and after preoperative radiochemotherapy for locally advanced rectal cancer. International Journal of Radiation Oncology, Biology, Physics, 41, 585-591.
  • TESFAIGZI, J., HOTCHKISS, J. A. and HARKEMA, J. R., 1998, Expression of the Bcl-2 protein in nasal epithelia of F344/N rats during mucous cell metaplasia and remodeling. American Journal of Respiratory Cell and Molecular Biology, 18, 794-799.
  • TSAI, S. T., JIN, Y. T., LEUNG, H. W., WANG, S. T., TSAO, C. J. and SU, I. J., 1998, Bcl-2 and proliferating cell nuclear antigen (PCNA) expression correlates with subsequent local recurrence in nasopharyngeal carcinomas. Anticancer Research, 18, 2849-2854.
  • UHLMANN, E. J., D'SA-EIPPER, C., SUBRAMANIAN, T., WAGNER, A. J., HAY, N. and CHINNADURAI, G., 1996, Deletion of a nonconserved region of Bcl-2 confers a novel gain of function: suppression of apoptosis with concomitant cell proliferation. Cancer Research, 56, 2506-2509.
  • VAIRO, G., INNES, K. M. and ADAMS, J. M., 1996, Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene, 13, 1511-1519.
  • VANDER HEIDEN, M. G., CHANDEL, N. S., SCHUMACKER, P. T. and THOMPSON, C. B., 1999, Bcl-xL prevents cell death following growth factor withdrawal by facilitating mitochondrial ATP/ADP exchange. Molecular Cell, 3, 159-167.
  • VANDER HEIDEN, M. G., CHANDEL, N. S., WILLIAMSON, E. K., SCHUMACKER, P. T. and THOMPSON, C. B., 1997, Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria. Cell, 91, 627-637.
  • VARFOLOMEEV, E. E., SCHUCHMANN, M., LURIA, V., CHIANNILKULCHAI, N., BECKMANN, J. S., METT, I. L., REBRIKOV, D., BRODIANSKI, V. M., KEMPER, O. C., KOLLET, O., LAPIDOT, T., SUFFER, D., SOBE, T., AVRAHAM, K. B., GONCHAROV, T., HOLTMANN, H., LONAI, P. and WALLACH, D., 1998, Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apol, and DR3 and is lethal prenatally. Immunity, 9, 267-276.
  • VEIS, D. J., SORENSON, C. M., SHUTTER, J. R. and KORSMEYER, S. J., 1993, Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell, 75, 229-240.
  • VOEHRINGER, D. W., MCCONKEY, D. J., MCDONNELL, T. J., BRISBAY, S. and MEYN, R. E., 1998, Bcl-2 expression causes redistribution of glutathione to the nucleus. Proceedings of the National Academy of Sciences, USA, 95, 2956-2960.
  • WANG, K., YIN, X. M., CHAO, D. T., MILLIMAN, C. L. and KORSMEYER, S. J., 1996, BID: a novel BH3 domain-only death agonist. Genes and Development, 10, 2859-2869.
  • WEI, M. C., ZONG, W. X., CHENG, E. H., LINDSTEN, T., PANOUTSAKOPOULOU, V., Ross, A. J., ROTH, K. A., MACGREGOR, G. R., THOMPSON, C. B. and KORSMEYER, S. J., 2001, Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science, 292, 727-730.
  • WILSON, G. D., GROVER, R., RICHMAN, P. I., DALEY, F. M., SAUNDERS, M. I. and DISCHE, S., 1996, Bcl-2 expression correlates with favourable outcome in head and neck cancer treated by accelerated radiotherapy. Anticancer Research, 16, 2403-2408.
  • WU, D., WALLEN, H. D., INDHARA, N. and NUNEZ, G., 1997, Interaction and regulation of the Caenorhabditis elegans death protease CED-3 by CED-4 and CED-9. Journal of Biological Chemistry, 272, 21449-21454.
  • YAMAMOTO, K., ICHIJO, H. and KORSMEYER, S. J., 1999, BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Molecular and Cellular Biology, 19, 8469-8478.
  • YANG, E., ZHA, J., JOCKEL, J., BOISE, L. H., THOMPSON, C. B. and KORSMEYER, S. J., 1995, Bad, a heterodimeric partner for Bel-XL and Bcl-2, displaces Bax and promotes cell death. Cell, 80, 285-291.
  • YANG, H. B., CHOW, N. H., SHEU, B. S., CHAN, S. H., CHIEN, C. H. and SU, I. J., 1999, The role of bcl-2 in the progression of the colorectal adenoma-carcinoma sequence. Anticancer Research, 19, 727-730.
  • YANG, X., CHANG, H. Y. and BALTIMORE, D., 1998, Essential role of CED-4 oligomerization in CED-3 activation and apoptosis. Science, 281, 1355-1357.
  • ZHANG, L., YU, J., PARK, B. H., KINZLER, K. W. and VOGELSTEIN, B., 2000, Role of BAX in the apoptotic response to anticancer agents. Science, 290, 989-992.
  • ZHU, W., COWIE, A., WASFY, G. W., PENN, L. Z., LEBER, B. and ANDREWS, D. W., 1996, Bcl-2 mutants with restricted subcellular location reveal spatially distinct pathways for apoptosis in different cell types. EMBO Journal, 15, 4130-4141.
  • ZOU, H., HENZEL, W. J., LIU, X., LUTSCHG, A. and WANG, X., 1997, Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell, 90, 405-413.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.